Immunotherapy and radiation after bladder cancer surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding radiation therapy to immunotherapy after bladder removal surgery can help prevent cancer from coming back. It's for people with advanced bladder cancer who have already started immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bladder cancer called urothelial carcinoma, including mixed types like squamous or glandular.
- You must have had your bladder removed (radical cystectomy) and lymph node removal within the last 48 weeks.
- You must be currently receiving immunotherapy called a checkpoint inhibitor after surgery.
- You must not have a neobladder (a new bladder made from intestine).
- You must not have had prior radiation to the pelvic area unless it's a different area and more than 4 weeks ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that adjusts to your body's changes during treatment. It aims to reduce side effects and improve accuracy for people with bladder cancer.
This trial tests whether radiation therapy (high-energy beams to kill cancer cells) can be a good treatment for bladder cancer that hasn't gone away after BCG therapy, offering an alternative to surgery to remove the bladder. It aims to see if this approach can control the cancer while possibly preserving your bladder.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This study tests a combination treatment for people with early-stage bladder cancer who want to avoid bladder removal. It uses a freezing technique (cryoablation) inside the bladder along with immunotherapy drugs to see if this can cure the cancer while keeping the bladder.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of a targeted drug (enfortumab vedotin) and focused radiation before surgery to remove the bladder. It aims to improve outcomes for people with bladder cancer that has not spread beyond the bladder.
Hear when a new Urothelial Carcinoma Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.